CooperCompanies Q3 FY2026 Earnings: Tax Benefit Drives GAAP EPS to $2.24

CooperCompanies (Nasdaq: COO) reported fiscal Q3 2026 revenue of $1.066 billion, up 1% year over year, while GAAP diluted EPS rose to $2.24 from $0.49. The EPS increase was primarily driven by a $307.2 million discrete tax benefit; non-GAAP EPS increased 4% to $1.15, and free cash flow rose 66% to $273.0 million.

Core Earnings Data

Revenue growth remained limited, with reported, constant-currency, and organic growth all at 1%. GAAP margins improved partly because the prior-year quarter included inventory and long-lived asset write-offs associated with a CooperSurgical product-line exit.

The adjusted results showed a more modest underlying improvement. Non-GAAP gross margin declined 60 basis points because of higher manufacturing costs and unfavorable foreign exchange, while non-GAAP operating margin increased 30 basis points through expense management and productivity initiatives.

Business and Segment Performance

CooperVision generated no reported or organic growth, as reductions in U.S. channel inventory weighed on results. Its geographic performance was mixed: EMEA grew, while the Americas and Asia Pacific declined. CooperSurgical provided the company’s growth, led by fertility products.

The 5% organic growth in fertility was the strongest category result. Within CooperVision, growth in toric and multifocal products was offset by a decline in sphere and other lenses. EMEA’s expansion was also insufficient to offset weaker results in the Americas and Asia Pacific.

Profitability, Cash Flow, and the Balance Sheet

Selling, general, and administrative expense fell to $401.3 million from $421.7 million. Research and development expense declined to $41.6 million from $44.6 million, while amortization expense decreased to $47.0 million from $50.0 million. These reductions helped adjusted operating margin increase despite gross-margin pressure.

Interest expense declined to $21.5 million from $25.4 million because of lower interest rates and lower average debt. Cash provided by operations was $341.7 million, and capital expenditures were $68.7 million, producing $273.0 million of free cash flow.

CooperCompanies repurchased approximately 4.9 million shares for $339.1 million during the quarter at an average price of $69.16. That amount exceeded quarterly free cash flow. Following an increase in the repurchase authorization from $2 billion to $3 billion, approximately $1.5 billion remained available.

At July 31, cash and cash equivalents were $154.7 million, compared with $110.6 million at the October 2025 fiscal year-end. Inventory increased to $911.5 million from $846.0 million over the same period. Short- and long-term debt totaled approximately $2.54 billion, compared with approximately $2.51 billion at fiscal year-end, with a larger portion classified as short-term debt.

The Tax Benefit, Not Operations, Drove Most of the GAAP Earnings Increase

The difference between GAAP and adjusted earnings is central to interpreting the quarter. CooperCompanies recorded $201.8 million of income before taxes but $432.8 million of net income because its income statement included a $231.0 million net tax benefit rather than a tax expense.

The main factor was a $307.2 million discrete benefit following the favorable completion of a U.K. tax authority examination involving the company’s fiscal 2021 transfer of intellectual property and related assets. This benefit drove GAAP EPS to $2.24, substantially above non-GAAP EPS of $1.15.

Excluding the reconciliation adjustments, non-GAAP net income increased only slightly to $221.5 million from $220.3 million. The adjusted figures therefore provide a clearer view of operating progress, which consisted of modest EPS growth, improved operating efficiency, and pressure on adjusted gross margin.

Financial Guidance

CooperCompanies updated its fiscal 2026 guidance. The release did not include the previous ranges, so the size and direction of the revisions cannot be determined from the provided information. The latest outlook points to continued divergence between CooperVision and CooperSurgical in the fourth quarter.

Management said the U.S. channel inventory reduction at CooperVision will continue to affect the fourth quarter. That expectation is reflected in the segment’s forecast for organic growth between negative 2% and zero, compared with positive 4% to 6% for CooperSurgical.

Risks Investors Need to Watch

• Continued CooperVision weakness: U.S. channel inventory reductions weighed on Q3 and are expected to continue affecting Q4. The segment’s Q4 organic growth guidance ranges from a 2% decline to no growth.
• Adjusted gross-margin pressure: Higher manufacturing costs and unfavorable foreign exchange reduced non-GAAP gross margin by 60 basis points. Further operating expense savings would be needed to offset continued pressure.
• GAAP earnings normalization: The $307.2 million tax benefit was discrete and drove most of the increase in GAAP net income and EPS, making the reported earnings jump less indicative of recurring operating performance.
• Litigation exposure: Accrued litigation liabilities increased to $316.5 million at July 31 from $0.7 million at the prior fiscal year-end. The company also recorded $274.4 million of litigation expense and associated legal costs during the first nine months of fiscal 2026.
• Capital allocation and debt: Quarterly share repurchases exceeded free cash flow, while total debt remained approximately $2.54 billion and shifted toward short-term classification. Future repurchase activity should be considered alongside cash generation and debt management.

Summary

CooperCompanies’ fiscal Q3 2026 combined minimal revenue growth with better operating cost control and substantially higher free cash flow. GAAP earnings were dominated by a one-time U.K. tax benefit, while adjusted results showed more modest progress and continued gross-margin pressure. The main operating question for the fourth quarter is whether CooperSurgical’s growth can offset ongoing CooperVision channel inventory reductions and weakness in several regions.